NEW YORK (GenomeWeb News) – Cancer Genetics priced its initial public offering at $10 per share today, expecting to raise gross proceeds of $6 million.

Shares of the Rutherford, NJ-based cancer diagnostics company were expected to begin trading today on the OTCQB Marketplace under ticker symbol "CGIX". Cancer Genetics is offering 600,000 shares of its common stock. The $10 price is at the low end of a $10 to $12 range that the company previously said it anticipated.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.

King's College London researchers examine the influence of school type and genetics on academic achievement.

FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.

In Science this week: early life experience influence somatic variation in the genome, and more.

Sponsored by
Thermo Fisher Scientific

In this webinar, the first in the “New Frontiers in Liquid Biopsy Research” series, Bea Bellosillo, head of pathology at the Hospital del Mar, will discuss her experience evaluating an early-access lung cancer panel that detects copy number variants and fusions.